Biotech IPOs staged a moderate recovery in 2024 but a muted end to the year showed how fragile the market remains for companies looking to launch.
Full year data shows 26 companies debuted on US exchanges last year, higher than the 21 achieved in 2023 and 22 in 2022, when a pandemic-fueled boom in biotech flotations abruptly ended
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?